Senators reach tentative deal on $10 billion in additional Covid funding, Romney says

Senators reach tentative deal on  billion in additional Covid funding, Romney says


U.S. Senator Mitt Romney (R-UT) walks through the Senate Subway on his way to a security briefing for senators on Russia’s invasion of Ukraine, on Capitol Hill in Washington, March 30, 2022.

Elizabeth Frantz | Reuters

Senate Republicans and Democrats have reached a tentative deal on $10 billion in additional Covid funding, less than half the sum that President Joe Biden had requested to shore up the nation’s pandemic response ahead of another potential infection wave.

Sen. Mitt Romney, R-Utah, told reporters he had a deal with Senate Majority Leader Chuck Schumer, D-NY, to cover the spending by redirecting money from the American Rescue Plan passed last year. The funding is far less than $22.5 billion the White House had requested from Congress.

Biden warned yesterday that the U.S. would not have enough Covid vaccine doses for all Americans this fall if Congress failed to act. The White House has also warned the uninsured would no longer have coverage for Covid testing, treatments and vaccinations. The U.S. would also face shortages of monoclonal antibody treatments, antiviral pills and Covid testing, according to administration officials.

It is not clear what the package would cover, as senators have not yet released details. The text of the agreement, when finished, would go the Congressional Budget Office to show that the funding is balanced by offsets.

House Democrats originally sought to pass $15 billion in Covid money earlier this month as part of a larger government funding package. However, House Speaker Nancy Pelosi pulled the Covid funding after Republicans and Democrats failed to agree on how to pay for it.

The GOP insisted on covering any new spending by clawing back money already appropriated for state and local governments, but Democrats rejected that demand.

A more contagious variant of omicron, BA.2, is spreading in the U.S. It now makes more than half of all infections that have undergone genetic sequencing, according to the Centers for Disease Control and Prevention. BA.2 has caused new Covid outbreaks in Europe and China, raising concerns the subvariant could do the same in the U.S.

White House chief medical advisor Dr. Anthony Fauci said earlier this month that BA.2 will likely cause an increase of infections in the U.S., though he doesn’t expect another surge. Epidemiologists say the U.S. could face another wave in the fall, as immunity from the vaccines wanes and people move indoors due to the colder weather.

CNBC Health & Science

Read CNBC’s latest global coverage of the Covid pandemic:



Source

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
Health

Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here

Wall Street is optimistic that Olema Pharmaceutical could be developing the next major breakthrough breast cancer treatment. Earlier this month, the company announced promising clinical data for its lead candidate palazestrant, an oral medication that is being evaluated in several trials for estrogen receptor-positive, or ER+, breast cancer. Shares of the clinical-stage biopharmaceutical company are up […]

Read More
This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’
Health

This biotech stock has jumped nearly 50% in 3 months. Its CEO says business is ‘growing substantially’

It’s been a stellar few months for shares of San Francisco-based biotech company Rigel Pharmaceuticals, which has approved treatments for rheumatology and oncology — as well as potential new drugs in the pipeline. The stock has jumped about 50% in just the last three months, earning it a spot on CNBC’s list of top performing […]

Read More
We’re raising our Eli Lilly price target — what a difference a quarter makes
Health

We’re raising our Eli Lilly price target — what a difference a quarter makes

Eli Lilly shares jumped Thursday after the drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications. The company also raised its full-year sales outlook for the second time in a row, inspiring confidence in the trajectory of the franchise. Revenue in the three months ended Sept. 30 jumped 54% year […]

Read More